AZD9291 and Simvastatin Interaction for Non-Small Cell Lung Cancer

"This research is no longer open for enrolment; the trial was initially posted on December 22nd 2014 and updated last August 31st 2022. If you are looking to participate in further studies, there are currently 1528 trials with openings for those diagnosed with non-small cell lung carcinoma (nsclc) as well as 137 clinical studies involving Simvastatin that still need patient recruitment."

"Per the information on clinicaltrials.gov, this particular medical trial is not accepting new participants; it was initially posted on December 22nd 2014 and most recently updated on August 31st 2022. However, there are 1,665 other trials that are actively searching for volunteers right now."

"As of now, 137 ongoing clinical trials involving simvastatin have been launched across 57 nations and 1242 cities. Merck Sharp & Dohme LLC initiated the first such study in 2005; it enrolled 80 patients and reached Phase 4 drug approval stage. Subsequently, 332 further studies have finished since then."

"A total of 52 patients, aged between 18 and 130 years old who have been diagnosed with non-small cell lung carcinoma (NSCLC), will be accepted into this trial. Additionally, male participants should comply to the use of barrier contraception until 6 months after they take their last dose while female candidates must provide evidence confirming that they are not in a childbearing period or utilize contraceptive measures if applicable. Furthermore, individuals should present an Eastern Cooperative Oncology Group performance standing at 0-1 without any decline over two weeks prior to enrollment as well as having a prognosis for life expectancy exceeding 12 weeks upon screening. Moreover, all applicants"

"As this trial requires that individuals are aged between 18 to 130, it is possible for those younger than 18 and older than 65 to apply. That said, there are 29 studies specifically targeting people under the age of eighteen while 1657 studies focus on adults over sixty-five years old."

"Malignant neoplasms can be managed with Simvastatin, and it also has efficacy for treating exercise-induced fatigue, peripheral vascular disease patient's symptoms, and diabetes mellitus."

"The safety of Simvastatin is rated a 1 due to the fact that it has only just entered Phase 1 trials, meaning there are limited findings on its efficacy and security."

"The sponsor for this clinical trial, AstraZeneca, has identified AUC of Simvastatin as the primary outcome to be measured. Blood samples will be taken on Days 1 and 31 at pre-dose 0.5, 1, 1.5, 2, 3 4 6 8 10 12 24 28 and 32 hours post simvastatin dose in Part A time frame. Additionally they'll determine secondary outcomes including CL/F of Simvastatin (rate and extent of absorption), AUC of Simvastatin Acid (pharmacokinetics) and Cmax of Simvastatin Acid (maximum plasma concentration)."

"At this moment, 137 clinical trials are being conducted on Simvastatin. Among them, 24 have reached the Phase 3 testing stage. While most of these studies occur in Uniondale, New york, a total of 5169 locations around the world are running related tests for this medication."